CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation

Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and gene expression profiling (GEP) of purified BM CD1...

Full description

Bibliographic Details
Main Authors: Dongzheng Gai, Jin-Ran Chen, James P. Stewart, Intawat Nookaew, Hasem Habelhah, Cody Ashby, Fumou Sun, Yan Cheng, Can Li, Hongwei Xu, Bailu Peng, Tarun K. Garg, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Fangping Chen, Bart Barlogie, Frits van Rhee, Guido Tricot, John D. Shaughnessy Jr., Fenghuang Zhan
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-09-01
Series:The Journal of Clinical Investigation
Subjects:
Bone Biology
Hematology
Online Access:https://doi.org/10.1172/JCI159527

Internet

https://doi.org/10.1172/JCI159527

Similar Items